Execution risks, valuations likely to cap upside in Zydus Lifesciences

Zydus Lifesciences’ Q1 revenue rose 6% led by India and overseas growth, but brokerages warn of margin pressure, loss of exclusivity and limited upside at current valuations

​Zydus Lifesciences’ Q1 revenue rose 6% led by India and overseas growth, but brokerages warn of margin pressure, loss of exclusivity and limited upside at current valuations